R1	Has_value Arg1:T2 Arg2:T3	
R2	AND Arg1:T1 Arg2:T2	
R4	Has_value Arg1:T6 Arg2:T7	
R5	Has_value Arg1:T8 Arg2:T9	
R3	Has_value Arg1:T8 Arg2:T10	
R6	Has_value Arg1:T6 Arg2:T5	
*	OR T6 T8
R7	AND Arg1:T4 Arg2:T6	
R8	Has_index Arg1:T15 Arg2:T16	
R9	Has_value Arg1:T14 Arg2:T17	
R10	Has_temporal Arg1:T14 Arg2:T15	
*	OR T20 T21
R11	Has_value Arg1:T19 Arg2:T20	
R12	Has_value Arg1:T23 Arg2:T24	
R13	Subsumes Arg1:T18 Arg2:T19	
R14	Has_value Arg1:T26 Arg2:T27	
R15	Has_qualifier Arg1:T29 Arg2:T30	
R16	Has_index Arg1:T31 Arg2:T32	
R17	Has_negation Arg1:T33 Arg2:T34	
R18	AND Arg1:T29 Arg2:T33	
R19	Has_temporal Arg1:T29 Arg2:T31	
R20	Subsumes Arg1:T18 Arg2:T23	
T1	Condition 14 35	chronic heart failure
T2	Measurement 39 65	New York Heart Association
T3	Value 66 81	Class II or III
T4	Measurement 85 119	left ventricular ejection fraction
T5	Value 123 128	= 40%
T6	Measurement 145 149	NYHA
T7	Value 150 158	class II
T8	Measurement 184 188	NYHA
T9	Value 189 198	class III
T10	Value 162 167	= 45%
T14	Measurement 202 218	hemoglobin level
T15	Temporal 219 241	at the screening visit
T16	Reference_point 222 241	the screening visit
T17	Value 242 263	between 9.5-13.5 g/dl
T18	Condition 269 284	iron deficiency
T19	Measurement 306 326	serum ferritin level
T20	Value 327 336	< 100µg/l
T21	Value 340 364	between 100 and 299 µg/l
T23	Measurement 371 394	transferring saturation
T24	Value 398 403	< 20%
T26	Person 406 409	Age
T27	Value 410 419	=18 years
T28	Post-eligibility 421 446	Obtained informed consent
T29	Procedure 455 478	pharmacological therapy
T30	Qualifier 448 454	Stable
T31	Temporal 479 502	during the last 4 weeks
T32	Reference_point 490 502	last 4 weeks
T33	Drug 526 535	diuretics
T34	Negation 504 525	with the exception of
